Search results
Researchers create 'chameleon' compound that targets drug-resistant brain cancers
Medical Xpress· 5 hours agoThe research, published in the Journal of the American Chemical Society, is a crucial step in the development of so-called "chameleon compounds" that may be used to target an array of pernicious ...
Walk six laps for Emerson the Brave, a 12-year-old battling cancer in Holland
The Holland Sentinel· 12 hours ago— A walkathon next week will raise funds for a local child battling brain cancer. West Ottawa Public...
New research platform assesses brain cancer mutations during surgery
Medical Xpress· 4 days agoBrain cancer is difficult to treat when it starts growing, and a prevalent type, known as a glioma, has a poor five-year survival rate. In a new study published ...
Why Are Younger People Getting Cancer?
US News Health· 5 days agoAt age 20, while studying sports management and marketing in college, Sean Kukoleck's life was disrupted by cancer. Cancer screenings are happening at younger ...
Agios cashes in on cancer drug again with $905M Royalty Pharma deal
BioPharma Dive via Yahoo Finance· 6 days agoThe deal involves royalties for a brain cancer drug Agios previously sold off and that Royalty...
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Zacks via Yahoo Finance· 5 days agoAgios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential...
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Zacks via Yahoo Finance· 6 days agoCandel (CADL) surges 431% in the year-to-date period, driven by positive developmental and...
Mother backs Epsom Derby auction to honour daughter
BBC via Yahoo News· 4 days agoFunds raised by the event will be used by the charity for research at its centres across the UK, with the aim of finding a cure for brain cancer. Emily,...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 2 days agoResults from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 days agoSapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation PR Newswire TARRYTOWN, N.Y., June 1, 2024 -Data demonstrates durable responses across 3 cohorts of patients with
